Evidence map›Paper›PMID 37698948›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Rerouting the GPS Directing Immunotherapy in Endometrial Cancer.

Rhea Jangra, Neesha C Dhani

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rhea JangraPrincess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.ORCID 0000-0002-3212-4775
Neesha C DhaniPrincess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.ORCID 0000-0002-0410-6932
Princess Margaret Cancer Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mismatch repair (MMR) status alone is insufficient to guide the use of PD-(L)1 monotherapy in patients with endometrial cancer. Additional biomarkers, including tumor mutational burden and combined positive score, may help to identify patients with MMR-proficient tumors with a high probability of benefit from PD-(L)1 monotherapy, and those with MMR-deficient tumors who might require combination strategies. See related article by Oaknin et al., p. 4564.

Indexed as

Colorectal NeoplasmsEndometrial NeoplasmsNeoplastic Syndromes, HereditaryBiomarkers, TumorDNA Mismatch RepairFemaleHumansImmunotherapyBiomarkers, Tumor

Identifiers

PMID37698948
OpenAlexW4386691447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.